PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
0.08
Positive OCF/share while GNPX is negative. John Neff might see an operational advantage over the competitor.
0.08
Positive FCF/share while GNPX is negative. John Neff might note a key competitive advantage in free cash generation.
No Data
No Data available this quarter, please select a different quarter.
1.12
1.25–1.5x GNPX's 0.83. Bruce Berkowitz would investigate if the competitor’s accruals hide weaker conversions.
No Data
No Data available this quarter, please select a different quarter.